​

Arvinas (ARVN) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

ARVN Stock Forecast

Arvinas (ARVN) stock forecast, based on 26 Wall Street analysts, predicts a 12-month average price target of $12.50, with a high of $18.00 and a low of $6.00. This represents a 15.21% increase from the last price of $10.85.

$5 $14 $23 $32 $41 $50 High: $18 Avg: $12.5 Low: $6 Last Closed Price: $10.85

ARVN Stock Rating

Arvinas stock's rating consensus is Buy, based on 26 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 20 Buy (76.92%), 5 Hold (19.23%), 1 Sell (3.85%), and 0 Strong Sell (0.00%).

Buy
Total 26 1 5 20 Strong Sell Sell Hold Buy Strong Buy

ARVN Price Target Upside V Benchmarks

TypeNameUpside
StockArvinas15.21%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts1212
Avg Price Target$10.00$10.50$13.83
Last Closing Price$10.85$10.85$10.85
Upside/Downside-7.83%-3.23%27.47%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Apr, 262881-19
Mar, 262881-19
Feb, 262881-19
Jan, 262791-19
Dec, 252791-19
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Mar 18, 2026Srikripa DevarakondaTruist Financial$10.00$10.96-8.76%-7.83%
Feb 24, 2026Wedbush$11.00$12.37-11.08%1.38%
Dec 17, 2025Barclays$18.00$11.9051.26%65.90%
Oct 30, 2025Jeet MukherjeeBTIG$14.00$9.5945.99%29.03%
Oct 15, 2025Goldman Sachs$6.00$9.41-36.24%-44.70%
Oct 07, 2025Piper Sandler$16.00$9.3670.94%47.47%
Sep 18, 2025BTIG$10.00$7.9226.26%-7.83%
Sep 18, 2025Sudan LoganathanStephens$14.00$7.7580.65%29.03%
Sep 16, 2025Barclays$16.00$7.64109.42%47.47%
Jun 02, 2025Andrew FeinH.C. Wainwright$24.00$7.33227.42%121.20%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Feb 24, 2026WedbushNeutralNeutralhold
Jan 06, 2026CitigroupNeutralBuyupgrade
Dec 17, 2025BarclaysOverweightOverweighthold
Oct 30, 2025BTIGBuyBuyhold
Oct 15, 2025Goldman SachsSelldowngrade
Oct 07, 2025Piper SandlerOverweightOverweighthold
Sep 18, 2025StephensOverweightOverweighthold
Aug 07, 2025H.C. WainwrightBuyBuyhold
Jun 09, 2025Canaccord GenuityBuyBuyhold
May 02, 2025BTIGBuyBuyhold

Financial Forecast

EPS Forecast

$-10 $-7 $-4 $-1 $2 $5 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-3.82$-5.31$-6.62$-2.77$-1.28---
Avg Forecast$-3.56$-4.94$-5.11$-3.15$-4.69$-4.51$-2.96$-1.22
High Forecast$-2.06$-2.87$-4.56$-2.31$-2.93$0.94$2.52$-0.54
Low Forecast$-5.89$-8.15$-5.68$-4.35$-8.05$-8.16$-7.26$-2.27
Surprise %7.30%7.49%29.55%-12.06%-72.71%---

Revenue Forecast

$50M $230M $410M $590M $770M $950M Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$53.60M$131.40M$78.50M$263.40M$262.60M---
Avg Forecast$74.13M$120.80M$168.51M$264.73M$214.45M$252.55M$358.29M$548.04M
High Forecast$111.40M$181.27M$197.30M$323.20M$341.08M$254.75M$363.26M$910.60M
Low Forecast$50.15M$81.88M$152.61M$232.71M$123.45M$250.35M$353.32M$311.26M
Surprise %-27.69%8.78%-53.42%-0.50%22.45%---

Net Income Forecast

$-500M $-370M $-240M $-110M $20M $150M Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-191.00M$-282.50M$-367.30M$-198.90M$-80.80M---
Avg Forecast$-215.82M$-220.51M$-367.30M$-184.72M$-341.42M$-363.59M$-282.85M$-67.88M
High Forecast$-172.65M$-176.41M$-293.84M$-128.03M$-162.87M$51.90M$139.59M$-29.75M
Low Forecast$-258.98M$-264.61M$-440.76M$-241.41M$-446.89M$-452.74M$-402.83M$-126.25M
Surprise %-11.50%28.11%-7.68%-76.33%---

ARVN Forecast FAQ

Is Arvinas stock a buy?

Arvinas stock has a consensus rating of Buy, based on 26 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 20 Buy, 5 Hold, 1 Sell, and 0 Strong Sell, reflecting a consensus that Arvinas is a favorable investment for most analysts.

What is Arvinas's price target?

Arvinas's price target, set by 26 Wall Street analysts, averages $12.5 over the next 12 months. The price target range spans from $6 at the low end to $18 at the high end, suggesting a potential 15.21% change from the previous closing price of $10.85.

How does Arvinas stock forecast compare to its benchmarks?

Arvinas's stock forecast shows a 15.21% upside, underperforming the average forecast for the healthcare stocks sector (15.45%) and underperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Arvinas over the past three months?

  • April 2026: 10.53% Strong Buy, 42.11% Buy, 42.11% Hold, 5.26% Sell, 0% Strong Sell.
  • March 2026: 10.53% Strong Buy, 42.11% Buy, 42.11% Hold, 5.26% Sell, 0% Strong Sell.
  • February 2026: 10.53% Strong Buy, 42.11% Buy, 42.11% Hold, 5.26% Sell, 0% Strong Sell.

What is Arvinas’s EPS forecast?

Arvinas's average annual EPS forecast for its fiscal year ending in December 2026 is $-4.51, marking a 252.34% increase from the reported $-1.28 in 2025. Estimates for the following years are $-2.96 in 2027, and $-1.22 in 2028.

What is Arvinas’s revenue forecast?

Arvinas's average annual revenue forecast for its fiscal year ending in December 2026 is $252.55M, reflecting a -3.83% decrease from the reported $262.6M in 2025. The forecast for 2027 is $358.29M, and $548.04M for 2028.

What is Arvinas’s net income forecast?

Arvinas's net income forecast for the fiscal year ending in December 2026 stands at $-364M, representing an 349.99% increase from the reported $-80.8M in 2025. Projections indicate $-283M in 2027, and $-67.877M in 2028.